BeiGene (ONC) reported Q1 adjusted earnings Wednesday of $1.22 per diluted American depositary share, swinging from an adjusted loss of $1.40 a year earlier.
Comparable analyst estimates were not readily available.
Revenue for the quarter ended March 31 was $1.12 billion, up from $751.7 million a year earlier.
Analysts surveyed by FactSet expected $1.13 billion.
For 2025, the biotech company continues to expect revenue of $4.9 billion to $5.3 billion.
Analysts polled by FactSet expect $5.07 billion.
Shares of the company were down more than 5% in recent premarket activity.
Price: 229.00, Change: -12.75, Percent Change: -5.27
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。